The core activity of SLA Pharma is the development of solutions for gastrointestinal diseases, particularly in the development of medications and treatments for GI disorders such as anal fissure, pilonidal sinus and colorectal medicine. The company focuses on clinical development and collaborates with international partners to develop innovative solutions for complex gastrointestinal diseases.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of therapies for gastrointestinal diseases
Development of targeted therapies for gastrointestinal and related diseases, focusing on digestive health, gastrointestinal oncology, and proctology.
Research and clinical studies
Research, development, and comprehensive clinical studies on the safety and efficacy of treatments, with a global research network and long-standing study experience.
Regulatory and market access support
Identification of new registration pathways, regulatory consulting, and accelerated approval processes for global markets.
Out-licensing of gastrointestinal therapies
Licensing market-ready, clinically validated gastrointestinal therapies to pharmaceutical companies, including regulatory documentation, technical dossiers, and global sales support.
In-licensing of gastrointestinal programs
In-licensing of programs for gastrointestinal and related indications, with regulatory expertise, commercialization, and global reach.
Knowledge
No knowledge articles yet
Once S. L. A. Pharma AG has claimed this profile, we'll publish editorial articles and case studies here together.